Topadur Pharma

Zurich-Schlieren, Switzerland, 7 September 2023

We are thrilled to announce that TOPADUR Pharma AG has once again been recognized as one of Switzerland's top 25 scale-up companies.

This achievement is a demonstration to our team's dedication and our partners' support.

We are grateful for this recognition and remain committed to pushing the boundaries of innovation in the years to come.

Please check out the link below.

‍

9.9.25

Press Release

Topadur secures FDA Orphan Drug Designation for TOP-N53

Topadur Pharma AG Secures FDA Orphan Drug Designation for TOP-N53 Targeting Digital Ulcers in Systemic Sclerosis

23.3.22

Press Release

The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.

7.4.22

Press Release

Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.